{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:37:56Z","timestamp":1786649876590,"version":"build-2736575974"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Pregabalin, a Gamma aminobutyric acid (GABA) analog, is widely prescribed for neuropathic pain, anxiety disorders, and epilepsy. However, its potential for misuse has raised significant public health concerns globally. The misuse of pregabalin is increasingly reported in our part of the world, where substance abuse is already a growing issue due to social, political, and psychological vulnerabilities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>This study aimed to assess the profile and prevalence of pregabalin abuse among patients visiting a de-addiction center in Kashmir.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and Methods:<\/jats:title>\n                    <jats:p>A cross-sectional study was conducted among 43 patients admitted to a de-addiction center in Kashmir over 3 months. Data on sociodemographics, substance use patterns, and reasons for misuse were collected using a semi-structured questionnaire.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Out of the 43 patients, 19 (44.2%) reported pregabalin as the primary substance abused, while 24 (55.8%) reported it as a secondary substance. Males constituted 93% of the sample, with the majority (72.1%) aged 18\u201335 years. Polysubstance use was observed in 65% of patients, primarily involving opioids (51.2%) and synthetic drugs such as tramadol and codeine (39.5%). Common reasons for abuse included anxiety relief (55.8%), pain relief (37.2%), and recreational use (30.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Pregabalin abuse is an emerging issue in Kashmir, often associated with polysubstance use and psychiatric comorbidities. Urgent steps are needed to regulate its availability, raise awareness regarding its abuse potential, and improve access to mental health services in the region.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ipj.ipj_71_25","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:01:41Z","timestamp":1759492901000},"page":"445-449","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and profile of pregabalin abuse in patients visiting a drug de-addiction center"],"prefix":"10.4103","volume":"34","author":[{"given":"Syed","family":"Mehvish","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Institute of Mental Health and Neurosciences Kashmir, Government Medical College, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marya","family":"Zahoor","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Institute of Mental Health and Neurosciences Kashmir, Government Medical College, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaheena","family":"Parveen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Institute of Mental Health and Neurosciences Kashmir, Government Medical College, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasir Hassan","family":"Rather","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Institute of Mental Health and Neurosciences Kashmir, Government Medical College, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshad","family":"Hussain","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Institute of Mental Health and Neurosciences Kashmir, Government Medical College, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heena","family":"Afzal","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Institute of Mental Health and Neurosciences Kashmir, Government Medical College, Srinagar, Jammu and Kashmir, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"R2-20260420","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40263-014-0164-4","article-title":"Misuse and abuse of pregabalin and gabapentin: Cause for concern?","volume":"28","author":"Schifano","year":"2014","journal-title":"CNS Drugs"},{"key":"R3-20260420","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/appi.ajp.2010.09091269","article-title":"Pregabalin abuse, dependence, and withdrawal: A case report","volume":"167","author":"Grosshans","year":"2010","journal-title":"Am J Psychiatry"},{"key":"R4-20260420","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00228-010-0853-y","article-title":"A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system","volume":"66","author":"Schwan","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"R5-20260420","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/hup.1098","article-title":"Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome","volume":"25","author":"Di Nicola","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"R6-20260420","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000355268","article-title":"Gabapentinoid abuse in order to potentiate the effect of methadone: A survey among substance misusers","volume":"20","author":"Baird","year":"2014","journal-title":"Eur Addict Res"},{"key":"R7-20260420","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40263-015-0303-6","article-title":"Abuse potential of pregabalin: A systematic review","volume":"30","author":"Schjerning","year":"2016","journal-title":"CNS Drugs"},{"key":"R9-20260420","article-title":"Proposed regulatory changes for Tapentadol and Pregabalin under Drugs Rules, 1945","year":"2024","journal-title":"Natl Health Policy Rep"},{"key":"R10-20260420","article-title":"Public notice on Pregabalin sale restrictions","year":"2024"},{"key":"R11-20260420","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1176\/appi.ajp.2015.15020262","article-title":"Prescription opioid misuse, abuse, and treatment in the United States: An update","volume":"173","author":"Brady","year":"2016","journal-title":"Am J Psychiatry"},{"key":"R12-20260420","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40265-017-0700-x","article-title":"Abuse and misuse of pregabalin and gabapentin","volume":"77","author":"Evoy","year":"2017","journal-title":"Drugs"},{"key":"R13-20260420","doi-asserted-by":"crossref","first-page":"723","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_307_24","article-title":"Understanding pregabalin misuse and dependence: Insights from a North Indian addiction treatment center","volume":"66","author":"Ghosh","year":"2024","journal-title":"Indian J Psychiatry"},{"key":"R14-20260420","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5530\/PTB.2021.7.2","article-title":"Analysis of gabapentinoids abuse-reports in the middle EASt and North Africa region utilizing the food and drug administration adverse event reporting system","volume":"7","author":"Alsheikh","year":"2021","journal-title":"PTB Rep"},{"key":"R15-20260420","doi-asserted-by":"crossref","first-page":"102635","DOI":"10.1016\/j.jflm.2023.102635","article-title":"Review of the demographic factors and toxicology related to deaths due to pregabalin in Northern Ireland","volume":"101","author":"Huddleston","year":"2024","journal-title":"J Forensic Leg Med"},{"key":"R16-20260420","doi-asserted-by":"crossref","first-page":"979","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_283_23","article-title":"Very high dose of pregabalin abuse: A case report","volume":"65","author":"Gupta","year":"2023","journal-title":"Indian J Psychiatry"},{"key":"R17-20260420","doi-asserted-by":"crossref","first-page":"738","DOI":"10.4103\/psychiatry.IndianJPsychiatry_475_19","article-title":"Pregabalin dependence","volume":"62","author":"Singh","year":"2020","journal-title":"Indian Journal of Psychiatry"},{"key":"R18-20260420","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1177\/02537176221122389","article-title":"Pregabalin use\/misuse:A source of consternation in western Punjab","volume":"45","author":"Aneja","year":"2023","journal-title":"Indian J Psychol Med"},{"key":"R19-20260420","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","article-title":"A decade of gabapentinoid misuse: An analysis of the European Medicines Agency\u2019s \u2018suspected adverse drug reactions\u2019 database","volume":"30","author":"Chiappini","year":"2016","journal-title":"CNS Drugs"},{"key":"R20-20260420","article-title":"NHS Surrey and Borders Partnership, Pharmacy Department, Farnham Road Hospital","year":"2020"},{"key":"R21-20260420","doi-asserted-by":"crossref","first-page":"639780","DOI":"10.3389\/fpsyt.2021.639780","article-title":"The French Addictovigilance Network (FAN). Gabapentinoid abuse in France: Evidence on health consequences and new points of vigilance","volume":"12","author":"Tambon","year":"2021","journal-title":"Front Psychiatry"},{"key":"R22-20260420","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/dar.12356","article-title":"Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity","volume":"35","author":"Owen","year":"2016","journal-title":"Drug Alcohol Rev"},{"key":"R23-20260420","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1186\/s12889-023-16051-6","article-title":"Misuse of pregabalin: A qualitative study from a patient\u2019s perspective","volume":"23","author":"Servais","year":"2023","journal-title":"BMC Public Health"},{"key":"R24-20260420","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00228-012-1464-6","article-title":"Pregabalin abuse and dependence in Germany: Results from a database query","volume":"69","author":"Gahr","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"R25-20260420","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40263-024-01064-5","article-title":"Trends in pregabalin use and prescribing patterns in the adult population: A 10-year pharmacoepidemiologic study","volume":"38","author":"Benassayag Kaduri","year":"2024","journal-title":"CNS Drugs"}],"container-title":["Industrial Psychiatry Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ipj.ipj_71_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:59:27Z","timestamp":1786647567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ipj.ipj_71_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ipj.ipj_71_25","relation":{},"ISSN":["0972-6748","0976-2795"],"issn-type":[{"value":"0972-6748","type":"print"},{"value":"0976-2795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"2025-03-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}